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Abstract 
In an experiment on white wild-type laboratory rats, it was shown that 90 minutes 
after intraperitoneal administration of cisplatin at a dose of 4 mg / kg as a solution heated to 
43 °C, the integral level of metallothionein significantly increased in the organs. 
Metallothionein actively binds toxic compounds of metals, including platinum. This may be 
one of the main reasons for developing resistance to platinum drugs with repeated courses of 
chemotherapy. Fast inductive synthesis of MT with the introduction of heavy metal 
compounds is one of the mechanisms of adaptation of the organism to the introduction of a 
highly toxic platinum compound. The binding of platinum to the sulfhydryl groups of 
metallothionein reduces the side effect of cisplatin while simultaneously decreasing its 
antitumor activity. It is not recommended to use the main metallothionein inducers (Zn, Se, 
antioxidants) in patients with cisplatin sensitive tumors before chemotherapy courses. 
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According to the National Chancery of Ukraine (NKR) in the NKR Newsletter 
"Cancer in Ukraine" [1] at the beginning of 2018 there were 1219100 people registered for 
cancer, 129000 people were registered for the first time in 2017. In the Odessa region, 68,600 
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people, of which 7,100 of which the disease was detected for the first time in 2017. It is 
expected that in the next 20 years the number of new cases will increase by about 70 %. The 
number of cancer cases is projected to continue to grow from 14 million in 2012 to 22 million 
in the next decades. 
The antitumor drug cisplatin has been widely used in the treatment of oncological 
diseases since 1978. Cisplatin is highly toxic as most heavy metal compounds. Due to faster 
metabolism in tumor cells and their active division, it is there that accumulates its highest 
concentration. Preparations of platinum have a pronounced damaging effect on the liver and 
especially the kidneys. It is dose-limiting for chemotherapy. 
The possibility of reducing side effects with an increase in the antitumor effect of 
cisplatin led to the development and implementation of a method of intraoperative 
intraperitoneal chemo-perfusion (HIPEC). This is a new progressive method of 
chemotherapy, which consists in perfusion of the peritoneal cavity with solutions containing 
cytotoxic agents at a temperature above the physiological norm (41-43 ° C) [2, 3]. HIPEC is 
conducted 30-90 minutes. Cisplatin achieves its maximum effectiveness during this time. 
HIPEC is a method of adjuvant therapy and allows pharmacologically to destroy microscopic 
tumor lesions in the abdominal cavity, which inevitably remain after surgical removal of the 
tumor ("macroscopic cytoreduction"). With HIPEC, traditional drugs for chemotherapy are 
used (Cisplatinum, Doxorubicin, Mitomycin C, Irinotecan, Oxaliplatin). The effectiveness of 
their use in peritoneal carcinomatosis in this case is much higher than with intravenous 
administration [4] due to higher local concentrations near the tumor. Local hyperthermia, as a 
rule, causes a positive immune response, an increase in the absolute number of lymphocytes, 
an increase in the ratio of CD8 / CD4, restoring normal ratios of regulatory and effector 
lymphocytes, enhances the functional activity of T cells. The start of the cytokine cascade is 
confirmed by an increase in the plasma level of interleukins — 1, 2, 3, 4, 6, 7, 8, 10, 11, 12, 
interferons alpha, gamma, colony-stimulating factors (granulocyte and lymphocyte), tumor 
necrosis factors, etc. These peptides not only have independent antitumour activity, but also 
significantly enhance the effectiveness of some chemotherapy drugs — antimetabolites, 
anthracycline antibiotics, vinalkaloids. There are also data on induction of hyperthermia of 
apoptosis of tumor cells [5]. 
Unfortunately, with relapse of the tumor, there is often resistance to platinum drugs, 
although initially the tumor was sensitive. Resistance to cisplatin is explained by three 
molecular mechanisms: an increase in DNA repair, a change in cellular accumulation and 
increased inactivation of the drug due to inappropriate binding [6]. 
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Sensitivity to platinum is returned if more than 2 years after the last chemotherapy 
with platinum (the probability that the patient will respond to platinum treatment, more than 
70 %) [7]. 
The biochemical mechanism of the antitumor effect of cisplatin has been sufficiently 
studied. However, today there are no specific transmembrane vectors for platinum 
preparations and the ways of their cellular transport are unknown. Reduction of antitumor 
activity is due to the fact that cisplatin is excreted from the cell by means of the 
transmembrane transport system. In addition, cisplatin binds to sulfhydryl groups of proteins 
and peptides (for example, such as glutathione or metallothioneins) and ceases to damage the 
DNA of tumor cells, causing their apoptosis. Finally, cisplatin reacts nonspecifically with 
various subcellular components: proteins, RNA and DNA. Although the advantage of binding 
decreases in the RNA > DNA > protein range, a decrease in the concentration of cisplatin 
available for DNA binding leads to a decrease in antitumor activity. 
Biomarkers of cisplatin resistance may be the cellular protein transporters of copper 
NER, CTR1 and CTR2, OCT2, ATP7A and ATP7B, glutathione GST and metallothioneins 
(MT) after additional clinical studies and standardization of methods and procedures of 
analysis [2]. 
The goal of our work — to determine the level of MT in liver and kidneys of rats in 
the modeling action of cisplatin with HIPEC. 
Materials and methods. In experiments, rats weighing 220-250 g under anesthesia 
were intraperitoneally injected with a solution of cisplatin heated to 44 ° C in a dose of 4 mg / 
kg in physiological saline (1 mg / animal). The control group under similar conditions was 
given a 0.9 % sodium chloride solution in order to take into account the effects of anesthesia 
and other effects unrelated to platinum, which affect the induction of MT [8]. The animals of 
the experimental and control groups were withdrawn from the experiment after 90 minutes. 
The MT content in the liver and kidney homogenate was determined by the substitution 
method for measuring the concentration of cadmium after the complete displacement of zinc 
and copper from MT after the removal of high molecular weight proteins and low molecular 
weight compounds. The cadmium content was measured by the atomic-emission method [8]. 
Results and its discussion. The MT content in the liver and kidney of laboratory 
animals is given in Table 1. The body area for a person weighing 80 kg is approximately 1.93 
± 0.04 m2. Those. the usual dose of cisplatin with HIPEC 50-100 mg/m2 is approximately 
1.2-2.4 mg/kg. Given the lower specific sensitivity to cisplatin, the dose was increased to 4 
mg / kg. In a preliminary experiment, it was found that this dose does not cause the death of 
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animals with a single intraperitoneal injection (LD50 = 6.2 mg/kg, death occurs after 8-10 
days). 
Table 1 
The content of MT in the liver and kidneys after 90 min. after intraperitoneal 
administration of a solution of cisplatin at a dose of 4 mg/kg (n = 7, P > 0.95, T = 43 ° C) 
 Liver kidney 
Group cisplatin control cisplatin control 
M (mean) 21,12 4,57 30,06 7,35 
Std. off (σ) 2,96 0,71 2,47 1,08 
Confidence interval 2,19 0,52 1,83 0,80 
m 1,12 0,27 0,93 0,41 
The maximum 25,70 5,55 33,11 9,12 
The minimum 16,99 3,75 25,96 5,97 
Note: the difference between experience and control is reliable, p < 0,01 
 
The average content of MT in the liver and kidneys is 90 minutes after the intravenous 
administration of cisplatin increases, respectively, in 4.62 and 4.09 times. Previously, it was 
described that induction of MT synthesis can occur through several fundamentally different 
mechanisms. The process of expression of MT genes is activated through: 
1. Metal response element (MRE)-binding transcription factor-1 (MTF-1), activated 
by "mobile" zinc ions. This transcription factor actively reacts to the entry of other toxic 
metals into the cell [9-11]. 
2. a glucocorticoid effector (GRE) [12], 
3. Activating STAT proteins (signaling transducers and activators) through cytokine 
signaling; 
4. antioxidants (or electrophiles), elements responsible for the reduction potential of 
cells (APE). 
Physiological synthesis of MT occurs rapidly enough, increasing several times during 
cell proliferation. Probably, with the introduction of cisplatin, the first mechanism is realized 
primarily. Previously, it was shown that overexpression of the gene coding metallothionein 
occurs in 70.6 % of patients diagnosed with esophageal cancer. MT is associated with 
resistance to cis-platinum: in patients with MTN (+) tumors after treatment with cis-platinum, 
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the five-year survival was 26 %, and for MTH (-) -56 % [13, 14], i.e. Overexpression of MT 
significantly reduces the effectiveness of chemotherapy with cisplatin. 
Conclusion. Fast inductive synthesis of MT with the introduction of heavy metal 
compounds is one of the mechanisms of adaptation of the organism to the introduction of a 
highly toxic platinum compound. The binding of platinum to the sulfhydryl groups of 
metallothionein reduces the side effect of cisplatin while simultaneously decreasing its 
antitumor activity. This means that patients with platinum-sensitive tumors are not 
recommended before the chemotherapy course to use the main inducers of metallothionein — 
preparations of zinc, selenium, and basic antioxidants. 
Prospects for further research. It is necessary to study the kinetics of MT synthesis, 
to determine after what time after cisplatin administration the concentration of MT has 
decreased to the basal level. 
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